GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

AstraZeneca AZN.L · GBp

Health Care · Pharmaceuticals · LSE · 🇬🇧 United Kingdom

FTSE 100

Compare

14,066.00p

+0.98%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

AstraZeneca — daily LSE:AZN

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View AstraZeneca on TradingView ↗
Market value
£218.15bn
Last close × shares
Volume
1.5m
Shares, 9 Nov 2026
Price to earnings
28.7
Dividend yield
2.28%

About AstraZeneca

Its shares trade on LSE under the ticker AZN.L. It has been listed since 21 September 2007. It is a member of the FTSE 100. In the fiscal year to 31 December 2025, it reported revenue of $58.74bn and net income of $10.22bn. At that date it held total assets of $114.07bn and shareholders' equity of $48.67bn.

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company is headquartered in Cambridge, Cambridgeshire. The company went IPO on 2007-09-21. The company focuses on discovery and development of products, which are then manufactured, marketed and sold. The company focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The company has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. The company has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. The company has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Figures and description from our data supplier, not checked against the company's own report.

More about AstraZeneca →

Latest on AstraZeneca

Our reporting

Next results

11 Feb 2027

Due on 11 Feb 2027. Analysts expect earnings of 1.73 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is AstraZeneca's ticker?

AstraZeneca trades as AZN.L on LSE, under ISIN GB0009895292.

What was AstraZeneca's last closing price?

14,066.00p on 9 Nov 2026. The figure is in GBp and is never converted.

When does AstraZeneca next report results?

Results are expected on 11 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.